Six New Drugs Will Drive Pancreatic Cancer Treatment Market to $2.9 Billion by 2021, says GBI Research

LONDON, January 14, 2016 /PRNewswire/ --

Pancreatic cancer treatment market will grow from its current level of $1.9 billion, with increased disease prevalence also a factor, says GBI Research.

A new report from business intelligence provider GBI Research - Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - states that there are six pancreatic cancer drugs expected to gain approval within the forecast period, all of which have demonstrated significant improvement in progression-free survival and/or overall survival in clinical trials.

Growth will occur across the eight major countries of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. For a free sample of this report, please visit the GBI Research website.

Analyst Adam Bradbury: "The six drugs expected to gain approval within the forecast period are Threshold's TH-302, Merrimack's Onivyde (in Europe), NewLink Genetic's HyperAcute Pancreas, Cancer Advances' G17DT, Immunomedics' Clivatuzumab Tetraxetan, and Incyte's Ruxolitinib Phosphate. However, these drugs are not expected to significantly impact the market because of their high cost-to-benefit ratio, which will severely limit their sales by 2021."

GBI Research's report also states that as pancreatic cancer is a disease with a very poor prognosis, developing drugs with adequate cost-to-benefit ratios is very difficult, and this is reflected in the disease's high attrition rate of 91% over all three phases of clinical trials.

Bradbury explains: "The poor revenue prospects associated with developing pancreatic cancer therapies will mean many potential investors see it as an unwise investment.Despite some improvements in failure rates, further elucidations of mutations and their effects on signalling pathways and disease progression will be required before effective combination therapies can be developed and a significantly lower failure rate achieved."

The analyst also notes that the current pancreatic cancer treatment market is dominated by the generic drug gemcitabine, which is the current standard of care and is widely used for its cost-effectiveness.

Bradbury adds: "Even if priced similarly to gemcitabine, the very poor efficacies of the pipeline drugs in comparison to existing therapies would not offer strong cost-to-benefit ratios. For this reason, most of the drugs likely to be approved during the forecast period will be administered as combination therapies, which will prevent companies charging premium prices and limit their market share."  

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook | LinkedIn | Twitter

For more information, please contact GBI Research on: +44-161-359-5817

SOURCE GBI Research